Brexucabtagene Autoleucel治疗复发或难治性套细胞淋巴瘤的标准实践结果:来自美国淋巴瘤CAR-T联盟的报告
该研究纳入2020年8月1日至2021年12月31日期间在美国16家机构接受白细胞分离术、拟制造商业brexu-cel治疗复发/难治性套细胞淋巴瘤的189例患者,其中168例(89%)接受了brexu-cel输注。最佳总缓解率和完全缓解率分别为90%和82%,中位随访14.3个月时6个月和12个月无进展生存率分别为69%(95%CI,61至75)和59%(95%CI,51至66)。1年非复发死亡率为9.1%,主要原因为感染;3级及以上细胞因子释放综合征和神经毒性发生率分别为8%和32%。
要点
- 标准实践中brexu-cel的最佳总缓解率和完全缓解率分别为90%和82%。
- 中位随访14.3个月时,6个月和12个月无进展生存率分别为69%(95%CI,61至75)和59%(95%CI,51至66)。
- 1年非复发死亡率为9.1%,主要原因为感染;3级及以上细胞因子释放综合征和神经毒性发生率分别为8%和32%。
核心结论
- 在标准实践环境中,brexu-cel的疗效和毒性与ZUMA-2试验报告的结果一致。
- 套细胞淋巴瘤的肿瘤内在特征以及可能近期暴露于苯达莫司汀,可能与较差的疗效结局相关。
研究设计与样本
- 纳入2020年8月1日至2021年12月31日期间在美国16家机构接受白细胞分离术、拟制造商业brexu-cel治疗复发/难治性套细胞淋巴瘤的患者。
- 共189例患者接受白细胞分离术,其中168例(89%)接受了brexu-cel输注。
- 在接受白细胞分离术的患者中,79%不符合ZUMA-2入组标准。
主要发现
- 最佳总缓解率和完全缓解率分别为90%和82%。
- 输注后中位随访14.3个月时,6个月和12个月无进展生存率分别为69%(95%CI,61至75)和59%(95%CI,51至66)。
- 1年非复发死亡率为9.1%,主要原因为感染。
- 3级及以上细胞因子释放综合征和神经毒性发生率分别为8%和32%。
- 单因素分析中,高危简化套细胞淋巴瘤国际预后指数、高Ki-67、TP53异常、复杂核型和母细胞样/多形性变异与brexu-cel输注后较短的无进展生存相关;近期暴露于苯达莫司汀(白细胞分离术前24个月内)在意向治疗单因素分析中与白细胞分离术后较短的无进展生存和总生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial, which showed best overall and complete response rates of 91% and 68%, respectively. We report clinical outcomes with brexu-cel in the standard-of-care setting for the approved indication. PATIENTS AND METHODS: Patients who underwent leukapheresis between August 1, 2020 and December 31, 2021, at 16 US institutions, with an intent to manufacture commercial brexu-cel for relapsed/refractory MCL, were included. Patient data were collected for analyses of responses, outcomes, and toxicities as per standard guidelines. RESULTS: Of 189 patients who underwent leukapheresis, 168 (89%) received brexu-cel infusion. Of leukapheresed patients, 79% would not have met ZUMA-2 eligibility criteria. Best overall and complete response rates were 90% and 82%, respectively. At a median follow-up of 14.3 months after infusion, the estimates for 6- and 12-month progression-free survival (PFS) were 69% (95% CI, 61 to 75) and 59% (95% CI, 51 to 66), respectively. The nonrelapse mortality was 9.1% at 1 year, primarily because of infections. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 8% and 32%, respectively. In univariable analysis, high-risk simplified MCL international prognostic index, high Ki-67, TP53 aberration, complex karyotype, and blastoid/pleomorphic variant were associated with shorter PFS after brexu-cel infusion. Patients with recent bendamustine exposure (within 24 months before leukapheresis) had shorter PFS and overall survival after leukapheresis in intention-to-treat univariable analysis. CONCLUSION: In the standard-of-care setting, the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.
引用
- Wang Y, Jain P, Locke FL, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023. PMID: 36753699. doi:10.1200/JCO.22.01797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。